This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .
Dipyridamole in the treatment of angina pectoris. A double-blind evaluation.
Since Heberden 's classic description of angina pectoris in 1768 , a satisfactory treatment has been sought . Nitroglycerin , which is the st and ard treatment , may have unpleasant side effects due to vasodilatation , and its duration of action is relatively short . From the rapid turnover of a multitude of alleged long-acting coronary vasodilators marketed , it is apparent that an ideal compound which is both effective and devoid of side effects has not been found . Fischer and Roch reported in 1951 the synthesis of a new group of compounds with two pyrimidine rings . One of these compounds , dipyridamole ( Persantine ) , was subsequently shown to produce a significant increase in coronary blood flow 1 and an increase in intercoronary anastomoses in dogs with surgically induced coronary artery constriction . 2 In patients with angina pectoris , several uncontrolled , or only partially double-blind , studies have indicated that dipyridamole produced subjective improvement . 3 - 6 In contrast , four double-blind studies 7 - 10 have
This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .